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2Abstract 22
The role of specific proportions of ω-3 EPA and DHA, in the modulation of 23
inflammation and oxidative stress markers associated to the progression of Metabolic 24
Syndrome was investigated. Potential inflammatory eicosanoids and docosanoids were 25
discussed together to biomarkers of CVD, obesity, inflammation and oxidative stress in 26
an animal model of metabolic disorders. Results evidenced a noteworthy health effect of 27
1:1 and 2:1 EPA:DHA proportions over 1:2 EPA:DHA based diets through a down-28
regulation in the production of strong pro-inflammatory ω-6 eicosanoids, a decrement of29
biomarkers of oxidative stress, and a modulation of fatty acid desaturase activities and30
plasma and membrane PUFAs towards greater anti-inflammatory profiles. Outcomes 31
contribute to the general knowledge on the health benefits of marine lipids and their role 32
on the progress of MetS, inflammation and oxidative stress. Results shed light on 33
controversial protective mechanisms of EPA and DHA to better design dietary 34
interventions aimed at reducing MetS.35
36
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1. Introduction 41
A sedentary lifestyle, malnutrition and low physical activity are risk factors associated 42
to the progression of Metabolic Syndrome (MetS) (Morrow, Minton and Roberts 1992). 43
MetS is defined as a cluster of risk factors for cardiovascular disease (CVD) and type-2-44
diabetes, which include decrease of HDL levels, hyperglycemia, hypertension, 45
hypertriglyceridemia, insulin resistance and obesity. MetS is characterized by a chronic46
3inflammation grade below the threshold of pain, which raises the concentration of 47
inflammatory markers in the systemic circulation (Sears 2005). In addition, oxidative 48
stress generated by an overproduction of reactive oxygen species (ROS) has been also 49
linked to the promotion of inflammation processes and MetS (Greene et al. 2011; Sears 50
and Ricordi 2012). Therefore, biomarkers for the diagnosis of these metabolic 51
dysfunctions would be desirable to early prevention or appropriate therapeutic 52
programs. A new approach for biomarker identification is the metabolic profiling that 53
comprises the identification and quantification of small molecular weight lipids 54
involved in the development and progression of many inflammatory conditions directly 55
correlated with MetS (Massey and Nicolaou 2013). Specific examples include the 56
strong pro-inflammatory eicosanoids and isoprostanes derived from ω-6 arachidonic 57
(ARA) acid (i.e. PGE2, PGF1α, PGF2α, TXA2, 8isoPGF2α, and so on) (Gao et al. 2006; 58
Massaro et al. 2008; Sears and Ricordi 2012), together to eicosanoids and docosanoids 59
derived from the ω-3 eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids that60
are considered less inflammatory compounds than ARA derivates (Kelly et al. 2011; 61
Waddington et al. 2001). Moreover, novel studies have suggested a potent anti-62
inflammatory and cellular protective activity of EPA and DHA resolvins (i.e., RvE1 and 63
RvD1) and protectins (i.e., PD1) (Lee 2012; Serhan et al. 2006). In addition, other 64
indexes have been associated with an increasing prevalence of chronic inflammatory 65
diseases related to metabolic disorders (McDaniel, Massey and Nicolaou 2011). One of 66
the most selective markers of cellular inflammation is the ratio ω-6/ω-3 in blood, the 67
higher ratio the greater pro-inflammatory conditions (Sears 2005). Moreover, fatty acid 68
desaturases (FAD) are important regulators of the endogenous fatty acid (FA)69
metabolism. A high desaturase activity related to oleic acid, palmitoleic acid, and ARA 70
production has been associated with obesity, hypertriacylglycerolemia, and insulin 71
4resistance. In contrast, the enhancement of FAD activity associated with EPA and DHA 72
biosynthetic pathways indicates insulin sensitivity, and the decrease of MetS and CVD 73
(Vessby et al. 2013).74
75
Regular consumption of marine ω-3 polyunsaturated fatty acids (PUFAs), mainly EPA 76
and DHA, results in metabolic health benefits by modulating specific lipid biomarkers 77
of cellular inflammation and oxidative stress and reducing CVD risk factors78
(Brahmbhatt et al. 2013; McDaniel, Massey and Nicolaou 2011; Neilson et al. 2012).79
Despite the growing evidence of the benefits of ω-3 supplements, there is no agreement 80
on a dietary recommended proportion of DHA and EPA (Harris et al. 2009). Therefore, 81
this investigation was aimed to delve deeper into the benefits exerted by the intake of 82
specific EPA:DHA ratios, targeting the formation of anti-inflammatory and pro-83
inflammatory lipid mediators on an animal model affected by metabolic abnormalities84
associated to MetS. The Koletsky model, a genetically obese hypertensive rat85
(SHROB), was used since it is a well-accepted pattern for studying MetS (Xu et al.86
2008). The formation of lipid mediators was considered together to biomarkers of 87
oxidative stress and inflammation like FAD activity, plasma and membrane FA profile,88
and ω-6/ω-3 ratio. Animals were fed standard diets enriched with fish oil containing 89
three different EPA:DHA ratios (1:1, 2:1, and 1:2), and were compared with animals 90
fed control diets based on soybean and linseed oils. Soybean oil is a rich source of ω-6 91
PUFAs, dietary precursors of pro-inflammatory lipid mediators; whereas, linseed oil is a 92
rich source of vegetable ω-3 PUFAs like linolenic acid (ALA), which slightly derives to 93
EPA and DHA. Lipidomic results were linked to previous research that presented the 94
effect of marine dietary interventions on biometric and clinical parameters of 95
spontaneously hypertensive obese rats (Molinar-Toribio et al. 2015).96
597
2. Materials and Methods 98
2.1 Animals and diets 99
Thirteen-week old female SHROB (n 35, Charles River, USA) rats were used as animal 100
models. Body weight was recorded on arrival (200-300g) and weekly thereafter. All the 101
specimens were kept in an isolated room with a constantly regulated temperature an 102
controlled humidity (222 oC, 5010 % humidity) on a 12h light/dark cycle with ad 103
libitum access to water and standard pelleted A04 chow for rodents (16% protein, 60% 104
carbohydrate, 3% fat, 4% fiber and 5% ash; Harlan Iberica, Barcelona, Spain). Animals 105
were randomized in five dietary groups: soybean, linseed, EPA/DHA 1:1, EPA/DHA 106
2:1, and EPA/DHA 1:2 group. Each group was fed a single weekly dose of 0,8 ml/kg of 107
the assigned oil supplement as listed in Supplementary Material S1. Oil supplements 108
were prepared as previously described and they had a similar fat and energy content 109
(Méndez et al. 2013). Briefly, 1:1, 2:1 and 1:2 EPA/DHA supplements were prepared 110
by blending adequate proportions of the commercially available fish oils from 111
AFAMPES 121 EPA (AFAMSA, Vigo-Spain), EnerZona Omega 3 RX (ENERZONA,112
Milano-Italy) and Oligen liquid DHA 80% (IFIGEN-EQUIP 98, Barcelona-Spain). 113
Soybean oil, obtained from cold pressing unrefined organic soybean oil, was from 114
Clearspring Ltd. (London, UK) and linseed oil, obtained from first cold pressing 115
unrefined organic flax oil, was from Biolasi S.L. (Ordizia, Guipuzcoa-Spain). The five 116
oils contained similar total amount of PUFA (55-66 mg per 100 mg of total fatty acid). 117
However, they significantly differed in the proportion of individual PUFAs. In fish oil 118
mixtures containing EPA/DHA ratios of 1:1, 2:1 and 1:2, EPA and DHA were the most119
abundant PUFA; together they amounted to approximately 50 mg per 100 mg of total 120
fatty acids. The sum of EPA and DHA in the orally administered soy and linseed oils 121
6only reached 1.75% of total fatty acids. In linseed oil, the short-chain omega-3 ALA and 122
omega-6 LA that made up 50% and 16.8% of total fatty acids respectively, were the 123
most abundant PUFA. In soybean oil, LA was the most abundant PUFA (47.5%) 124
whereas the content of ALA was 4%. After a 2-week adaptation period, the oils were 125
administrated for 13 weeks and the experiment ended when rats were 28 weeks old.126
Then, rats were fasted overnight, anesthetized and sacrificed by exsanguination. 127
Handling and killing of the animals were in full accordance with the European Union 128
guidelines for the care and management of laboratory animals and the pertinent 129
permission was obtained from the CSIC Subcommittee of Bioethical Issues (ref. 130
AGL2009-12 374-C03-03).131
132
2.2 Fatty acid analysis of the oil supplements 133
To determine the fatty acid composition of the oil supplements, 0.6 mg of lipid were 134
methylated following the method of Lepage and Roy (Lepage and Roy 1986). The fatty 135
acid nonadecanoic acid was used as an internal standard. The FA methyl esters were 136
analyzed by gas chromatography-flame ionization detector (GC-FID). Results are 137
shown in Supplementary Material S1.138
139
2.3 Plasma and erythrocyte sampling for FA analysis 140
Blood samples were collected via cardiac puncture into polypropylene tubes containing 141
EDTA (1 mg/ml), and centrifuged for 15 min, at 4
o
C and 850 g. After that, the buffy 142
coat was removed and the packed erythrocyte cells were washed according to the 143
protocol developed by Sonenberg (Tsukamoto and Sonenberg 1979). Erythrocytes were 144
collected into clean polypropylene tubes, frozen and kept at -80 
o
C until required. Then, 145
7erythrocyte free plasma was supplemented with 5 mM PMSF (protease inhibitor) and 146
immediately stored at -80 ºC until required.147
148
2.4 Extraction and analysis of plasma TFA and FFA 149
Plasma samples for the analysis of total FA (TFA) (30 µL) and free FA (FFA) (100 µL) 150
were first spiked with an internal standard of nonadecanoic acid (Larodan Fine 151
Chemicals, Malmö-Sweden), and then, extracted with a dichloromethane: methanol:152
water mixture (2:2:1, v/v) using a Bligh and Dyer procedure (Puttmann et al. 1993).153
TFA were directly analyzed in the organic phase after dryness under a stream of 154
nitrogen gas. Then, samples were transesterified and analyzed by GC-FID (Clarus 500, 155
Perkin–Elmer) following the method of Lepage and Roy (Lepage and Roy 1986). To 156
isolate the FFA fraction, the resulting lipid mixture obtained from the Bligh and Dyer 157
extraction was subjected to solid phase extraction (SPE) on aminopropyl cartridges 158
(500mg, 6mL, Biotage, Uppsala-Sweden) as Kaluzny et al. previously described 159
(Kaluzny et al. 1985). Solvent was removed under a stream of nitrogen and then 160
subjected to transesterification and GC-FID analysis. Results are shown in Tab.1.161
162
2.5 Extraction and analysis of FA from erythrocyte membranes 163
To study the profile of FA from the erythrocyte membranes, lyophilized erythrocyte 164
samples (50 mg) were extracted by Bligh and Dyer procedure (Bligh and Dyer 1959). 165
The organic layer was dried under nitrogen and the lipid content was gravimetrically 166
quantified. Finally, an aliquot of organic phase containing 0.15 mg of lipids was dried, 167
the internal standard was spiked and transesterification and GC analysis were done as 168
before indicated to plasma FA (Tab.1).169
170
82.6 Fatty acid desaturase indexes measurement 171
Desaturase activities in dietary supplemented groups were measured using a validated 172
methodology from the TFA data (Warensjo et al. 2009). FAD indexes were calculated as 173
product/precursor ratio for: Stearoyl-CoA (SCD-16 or SCD-18) = [palmitoleic (16:1 ω-174
7)/palmitic (16:0)] or [oleic (18:1 ω-9)/stearic (18:0)]; 5D = [ARA (20:4 ω-6)/DGLA175
(20:3 ω-6)] and [DHA (22:6 ω-3)/DPA (22:5 ω-3)]; 6D = [DGLA (20:3 ω-6)/LA (18:2 176
ω-6)]; and 5/6D = [EPA (20:5 ω-3)/ALA (18:3 ω-3)]. Results are shown in Tab.2.177
178
2.7 SPE method for lipid metabolites isolation from plasma samples 179
ARA, EPA and DHA oxidized lipid mediators were extracted from plasma samples by 180
following a previously developed SPE method (Dasilva et al. 2014). Briefly, samples 181
(90 µL) were diluted with 30% cold methanol (v/v) to a final volume of 1 mL, and then 182
spiked with the internal standard 11HETE-d8. After centrifugation (1800g, 10 min, 4º 183
C), samples were loaded into conditioned Oasis-HLB cartridges (60mg, 3mL, Waters, 184
MA-USA). Then, cartridges were washed with 5mL 15% methanol (v/v), 5 mL Milli-Q 185
water and 2.5 mL hexane in succession. After sorbent dryness, analytes were eluted 186
with 2 mL methyl formate. Extracts were evaporated to dryness, re-dissolved in 30 µL 187
ethanol, and analyzed by LC-ESI-MS/MS. Standard solutions of lipid mediators were 188
purchased from Cayman Chemicals (Ann Arbor, MI, USA). Methanol and Water, 189
Optima LC-MS, were purchased from Fisher Scientific (New Jersey, USA).190
191
2.8 Analysis of lipid metabolites by LC-ESI-MS/MS 192
Lipid mediators were quantified according to the previously developed methodology 193
(Dasilva et al. 2014) and results are shown in Tab.3. Briefly, analyses of SPE extracts 194
were carried out on an Agilent 1260 Series (Agilent, Palo Alto, CA) coupled to a linear 195
9ion trap mass spectrometer LTQ Velos Pro with ESI (Thermo Fisher, Rockford, IL, 196
USA). A Waters C18-Symmetry column, 150×2.1 mm, 3.5 μm (Milford, MA, USA) 197
protected with a 4×2 mm C18 guard cartridge provided by Phenomenex (Torrance, CA, 198
USA) was used. A binary eluent system of water (A) and methanol (B), both with 199
0.02% (v/v) of formic acid, was used as mobile phase. The injection volume was set to 200
10 μL, ESI source operated in negative ion mode, and MS/MS conditions has been 201
reported in detail elsewhere (Dasilva et al. 2014). The quantification of target 202
compounds was made using the most intense, or selective, ions in their product ion scan 203
MS/MS spectra. Retention times for target compounds and individual MS/MS 204
parameters are summarized in Supplementary Material S2.205
206
2.9 Statistical analysis 207
Data presented are expressed as mean ± SD. Statistical analyses were performed by one-208
way analysis of variance (ANOVA) with R free software (version 386 3.1.0). Non-209
parametric Kruskal Wallis analyses were required when data distribution did not fit a 210
Gaussian model or heterogeneity was found in variances. The means were further 211
compared by the post-hoc test Fisher least square difference (Fisher LSD) and 212
significant differences were set at p<0.05. Pearson test was used in order to determine 213
statistical correlations between metabolites and PUFA intake, CRP, SOD, GPX and 214
CAT levels.215
216
3. Results 217
Weekly measurements demonstrated that there were not significant differences in food 218
intake, body weight gain (final body weight ranged between 570-610g for all animals) 219
or adiposity (ranged over 6.3-7.8 %) between experimental groups that could cause 220
10
differential effects between diets. Considering that the amount of total ω-3 in the marine 221
enriched diets was similar, 50% of the total fat amount, the results here described 222
strictly illustrate the effects produced by the different EPA/DHA dietary proportions 223
compared with a control ω-6 diet and control ω-3 ALA diet. The measured parameters 224
were correlated with the development/prevention of inflammatory processes, oxidative 225
stress and metabolic disorders (McDaniel, Massey and Nicolaou 2011; Vessby et al.226
2013).227
228
3.1 Effect on plasma FFA profile, FA incorporation into tissues, and ω6/ω3 ratios. 229
Noticeable differences were observed in FA profiles in plasma and FA incorporated into 230
erythrocyte membranes between animals fed with 1:1 and 2:1 EPA/DHA diets when 231
compared with 1:2 EPA/DHA, linseed and soybean groups. In detail, a significant 232
enrichment of ω-3 EPA and DHA levels in plasma and incorporated into membranes233
was observed by 1:1 and 2:1 treatments, meanwhile the lowest levels were achieved by 234
soybean one (p<0.05). The opposite trend was observed in ω-6 PUFAs levels. Animals 235
fed 1:1 and 2:1 fish diets produced the lowest total amount of ω-6 PUFA (i.e., ARA), 236
meanwhile soybean treatment significantly enhanced the production of total ω-6 PUFA 237
(p<0.05) in both, plasma and erythrocyte membranes. Intermediate levels of ω-3 and ω-238
6 PUFAs were found in 1:2 and linseed diets. It is remarkable that the intervention with 239
1:2 EPA:DHA did not enhance DHA level neither in plasma nor in membranes as 240
initially expected according to the high content of this PUFA on the diet. The main ω-6 241
PUFA from soybean oil (linoleic acid, LA) was found higher in plasma from soybean 242
group, but poorly incorporated into membranes when compared with other treatments 243
(p<0.05). ALA level (main ω-3 PUFA from linseed) in plasma significantly increased by 244
linseed oil intervention as expected, but it was only incorporated into erythrocyte 245
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membranes by animals fed linseed oil. Results also highlighted a significant reduction 246
of plasma oleic acid by three EPA/DHA interventions compared with soybean and 247
linseed ones (p<0.05). As a consequence of the FA modulation by the diet, the 248
inflammatory index ω-6/ω-3 in plasma and membranes was found significantly reduced 249
in animals fed 1:1 and 2:1 supplements (p<0.05) compared with the other groups.250
Soybean treatment produced the highest ratio; meanwhile intermediate values were 251
obtained for 1:2 and linseed groups (p<0.05) (Tab.1). 252
253
3.2 Effect on FAD activity 254
Results outlined that the studied supplements did not exert a different influence on 255
SCD-16 [palmitoleic/palmitic], and 6D [DGLA/LA] activities (Tab.2). Nevertheless,256
SCD-18 [oleic/stearic] was significantly reduced by 1:1 and 2:1 supplementations when 257
compared with soybean diet (p<0.05). Moreover, ω-3 EPA/DHA diets were effective in 258
down regulating 5D [ARA/DGLA] activity when compared with soybean and linseed 259
diets (p<0.05). On the other hand, results highlighted the ability of EPA and DHA intake260
on harnessing D [EPA/ALA] and 5D [DHA/DPA] activities in comparison with 261
linseed and soybean groups (p<0.05). 262
263
3.3 Formation of plasma lipid mediators depending on the ingested amount of ARA, 264
EPA and DHA265
Several hydroxyl and hydroperoxyl derivates, thromboxane and prostaglandin 266
metabolites from ARA, EPA and DHA were quantified (Tab.3). In detail, four EPA267
eicosanoids from the family of hydroxides (12HEPE), hydroperoxides (15HpEPE and 268
12HpEPE), and a thromboxanes (TXB3) were identified. From DHA, the 17HDoHE 269
(hydroxide) and 17HpDoHE (hydroperoxide) were detected. One hydroxide and one270
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prostaglandin derived from ARA, 11HETE and PGE2 respectively, were found in 271
plasma samples. Finally, isoprostanes, leukotrienes, resolvins, and protectins were not 272
detected. The quantitative and statistical analysis between groups revealed that dietary 273
interventions with linseed, 1:1 and 2:1 EPA/DHA oils generally decreased the overall 274
levels of lipid mediators when compared with 1:2 and soybean groups.275
276
In detail, levels of EPA eicosanoids, 12HEPE and TXB3, significantly increased in 1:2 277
diet compared with other diets (p<0.05). Levels of EPA hydroperoxides, 12 and 278
15HpEPE, were significantly lower in 1:1, 2:1 and linseed diets when compared with 279
1:2 and soybean ones (p<0.05). A similar pattern was found for docosanoids derived 280
from DHA: animals fed 1:2 diet enhanced the production of 17HDoHE compared with 281
other groups (p<0.01); and the level of 17HpDoHE was found to be significantly higher 282
in 1:2 and soybean groups than 1:1, 2:1 and linseed ones (p<0.001). The strong pro-283
inflammatory prostaglandin derived from ARA, PGE2, was significantly less-produced 284
by dietary 1:1, 2:1 and linseed interventions; meanwhile soybean and 1:2 diets produced 285
the highest concentration (p<0.05). In addition, 11HETE (ARA hydroxide) level was 286
strongly reduced by EPA/DHA and linseed diets when compared with soybean one 287
(p<0.05). Therefore, dietary 1:1 and 2:1 fish oil interventions reduced more the 288
production of inflammatory hydroxides, hydroperoxides, and prostaglandins than 1:2, 289
soybean and linseed ones.290
291
The analysis of the PUFA precursors (EPA, DHA, and ARA) showed the highest levels 292
by 1:1 and 2:1 fish diets when compared with 1:2, linseed and soybean groups 293
(p<0.001). Finally, other searched compounds as 15HEPE, 5HEPE, 8iso-PGF3α, 8iso-294
PGF2α, PGD3, PGE3, 11HDoHE, 4HDoHE, RvD1, PDx, and LTB4 were not produced by 295
13
any of the diets or were under the detection limits of the method. 296
297
The correlation analysis between lipid mediator levels in plasma and the dietary intake 298
of EPA and DHA, showed that the intake of EPA (20C FA) exerted a different effect on299
metabolite production when compared with 22C DHA (Tab.4). In detail, an increase in300
the ingested amount of 20C FA produced an enhancement in plasma levels of free EPA 301
and DHA (positive Pearson indexes over 0.7-0.8), however an increase in the ingested 302
amount of 22C was weakly correlated with a higher level of EPA and DHA in plasma 303
(positive indexes over 0.3-0.4). Interestingly, the correlation between the uptake of EPA 304
and DHA and the production of their primary (hydroperoxides) and secondary 305
(hydroxides and thromboxane) oxidation metabolites follow the opposite tendency: an 306
increase in the ingested 20C produced a decrease of these metabolites (negative 307
correlation indexes); meanwhile, an increase in the ingested 22C produced positive 308
correlations with the exception of 12HpEPE. In addition, high inverse correlations were309
found between levels of strong pro-inflammatory metabolites from ω-6 ARA (11HETE 310
and PGE2) and EPA uptake (negative Pearson indexes over 0.84-0.98). Nevertheless, 311
the decrease of ARA metabolites was weakly correlated with the increase of 22C uptake 312
(negative Pearson indexes over 0.3-0.5). Therefore, results suggested that an increase in 313
the ingested amount of EPA produced a down-regulation of PUFA oxidation, being 314
particularly significant a minor production of ARA metabolites. However, the increase 315
of DHA reduced this effect and even enhanced the production of oxidized metabolites.316
317
3.4 Dietary interventions effect on general biochemical parameters. 318
Biochemical parameters related with MetS were previously reported to describe the 319
influence of dietary interventions on phenotypic characteristics of genetically obese and 320
14
hypertensive rats (Molinar-Toribio et al. 2015). Several CVD risk factors, inflammation 321
markers and oxidative stress parameters are here compared: TFA, total triglycerides 322
(TG), total cholesterol (TC), high/low density lipoproteins (HDL, LDL), glycated 323
hemoglobin (HbA1c), reactive C-protein (CRP), and antioxidant enzymes activity of the 324
studied animals (Supplementary Material S3). 325
326
Briefly, it was observed that dietary interventions with 1:1 and 2:1 EPA:DHA ratios 327
exerted a significant reduction of plasma TFA, TG, TC, LDL, and CRP levels (p<0.05) 328
when compared with the soybean group (intermediate levels were achieved with 1:2 and 329
linseed diets). The correlation analysis showed that the increase of the inflammatory 330
CRP index was closely correlated with higher hydroperoxides and ω-6 inflammatory 331
eicosanoids production (positive Pearson indexes over 0.8-0.99) and lower EPA and 332
DHA concentrations (negative Pearson indexes over 0.8-0.9). No differences between 333
diets were observed in HDL content and 1:1 and 2:1 groups enhanced HDL/LDL ratio 334
compared with soybean (p<0.05); meanwhile, 1:2 and linseed animals produced 335
intermediate levels. The glycaemia results showed a significant decrease in the HbA1c336
in all animals supplemented with ω-3 fish and linseed oils (p<0.05). Finally, the 337
concentration of antioxidant enzymes in erythrocyte membranes showed lower levels in 338
animals fed soybean oils. In detail: superoxide dismutase (SOD) was enhanced by ω-3 339
fish and linseed supplements; glutathione peroxidase (GPX) values were higher for 1:1 340
and 2:1 meanwhile 1:2 and linseed animals produced similar levels as soybean one.341
Catalase (CAT) was highly produced by 2:1 diet and intermediate values were achieved 342
by 1:1, 1:2 and linseed diets. Generally, positive correlation indexes were found 343
between these enzymes concentrations and EPA and DHA levels; meanwhile, negative 344
indexes correlated the enzymes concentration and PUFA oxidation products.345
15
346
4. Discussion 347
This investigation noteworthy suggests a health effect of 1:1 and 2:1 EPA/DHA 348
interventions by reducing inflammatory eicosanoids and docosanoids synthesis from ω-349
3 EPA and DHA and ω-6 ARA, and modulating the FFA profile and FA incorporation 350
into tissues to reduce the inflammatory index ω-6/ω-3. These results are in agreement 351
with a reduced level of several inflammation and CVD risk factors, and an increased 352
level of relevant endogenous antioxidant enzymes. These data are consistent with a353
higher anti-oxidant and anti-inflammatory capacity of EPA vs DHA, and fish ω-3 oils vs354
vegetal ω-3 and ω-6 oils previously observed in a healthy animal model of Wistar rats 355
(Dasilva et al. 2015).356
357
Lipoxygenase (LOX) enzymes are involved in the pathways of formation of primary 358
and secondary oxidation products (hydroperoxides and hydroxides, respectively) from 359
EPA and DHA. Through cyclooxygenase (COX) activity, TXB3 from EPA and the 360
strong pro-inflammatory compounds derived from ARA (11HETE and PGE2), are 361
produced (Massey and Nicolaou 2013). Results from the fish oil groups revealed that 362
1:1 and 2:1 diets produced lower levels of these metabolites in addition to linseed diet.363
Therefore, these three diets seems to be more effective down-regulating the activity of 364
LOX and COX enzymes responsible of the synthesis of pro-inflammatory derived 365
eicosanoids and docosanoids. Hydroperoxides and hydroxides from ω-3 EPA and DHA366
have been described as weaker inflammatory substances than the corresponding ω-6 367
ARA derivates (Sears and Ricordi 2012; Shearer et al. 2010). In the same way, TXB3 is 368
related to the inflammatory response and is a competitor product of COX enzymes that 369
also produce strong pro-inflammatory series-2 thromboxanes from ARA (McDaniel, 370
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Massey and Nicolaou 2011). ARA eicosanoids, PGE2 and 11HETE, have been widely 371
studied and identified as key pro-inflammatory signaling molecules with pro-372
aggregating, vasoconstrictive and immunosuppressive properties closely correlated with 373
the development of MetS (Ferreiro-Vera et al. 2011).374
375
The antioxidant endogenous system described by SOD, GPX and CAT enzymatic 376
activities was significantly enhanced by fish diets, and specially by 1:1 and 2:1 377
EPA:DHA ratios. Accordingly, Pearson indexes show a strong positive correlation 378
between SOD, GPX and CAT concentrations and EPA and DHA levels in plasma; 379
meanwhile, the production of eicosanoids and docosanoids was reduced. Both findings380
suggested an antioxidant effect in 1:1 and 2:1 diets and a decrease of oxidative stress. 381
Other studies have also found an improvement of the antioxidant SOD (Garrel et al.382
2012; Yessoufou et al. 2006) and CAT (Chapman, Morgan and Murphy 2000) activities 383
after ω-3 PUFA supplementation. Therefore, the ability of 1:1 and 2:1 supplemented 384
diets to ameliorate the production of inflammatory oxidized lipids could be closely 385
correlated with the enhancement of the antioxidant system. As a consequence, the free 386
PUFA levels were higher and lipid metabolites concentrations lower in these groups 387
than in the other ones. The fish-enriched diet with the 1:2 EPA:DHA ratio was less 388
effective decreasing levels of inflammatory metabolites compared to 1:1 and 2:1, and it 389
even produced the highest concentrations for some compounds compared to controls. 390
Interestingly, 1:2 diet showed lower levels of antioxidant enzymes than 1:1 and 2:1, and 391
a major production of lipid oxidized metabolites that can be associated to a higher up-392
regulation of LOX and COX activity.393
394
Richard et al. (2008) demonstrated that supplementations with EPA and DHA (and 395
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specially EPA) resulted in lower formation of ROS and in higher inhibition of 396
superoxide anion than ω-6 enriched diets in cell models. In addition, levels of free fatty 397
acids (ARA, EPA and DHA) were found higher after fish oil treatments with a balanced 398
proportion EPA/DHA 1:1 or higher EPA (2:1). It seems that these diets produce a 399
higher preservation of PUFA from oxidation that leads to a lower production of the 400
corresponding lipid mediators as it was pointed above. In concurrence with these 401
findings, the statistical correlation analysis between the weekly intake of EPA and DHA402
and further production of lipid metabolites, suggested that an increase in the amount of 403
DHA in the diet may enhance the oxidation of PUFAs, and thus, stimulates the 404
production of lipid oxidized derivates. Nevertheless, a higher dose of EPA leads to a 405
protective effect on PUFAs oxidation and produced less derived inflammatory 406
metabolites. According to Di Nunzio et al., the propensity of fatty acids to oxidation is 407
theoretically proportional to the degree of instauration (Di Nunzio, Valli and Bordoni 408
2011). Considering the higher unsaturation level of DHA molecule (n=6) than EPA one 409
(n=5), fish oil diet with a higher proportion of DHA (1:2 EPA:DHA ratio) could 410
generate stronger oxidative conditions that activate LOX enzymes; and thus, the 411
production of inflammatory metabolites.412
413
Fatty acid desaturases are one of the main targets for the treatment of metabolic related 414
disorders, and the rate-limiting step in the biosynthesis of different FFA. FFA released 415
from adipose tissue into plasma are important because they exert relevant functions as 416
signaling molecules participating in inflammation processes and oxidative stress 417
(Martins et al. 2012). According to FAD indexes, diets rich in ω-3 fish oils up-regulated418
 and  desaturases involved in the transformation of ALA into EPA and DHA, 419
meanwhile the activity of these enzymes to produce ARA from LA was reduced. 420
18
Moreover, results reveal a down-regulation of SCD-18 in 1:1 and 2:1 diets that is 421
responsible of the biosynthesis of oleic acid, a key factor in the development of obesity 422
(Mutch et al. 2007). These results are in agreement with FFA composition of plasma 423
and FA incorporated into erythrocyte membranes. FA profiles were enriched in ω-3 424
EPA and DHA by 1:1 and 2:1 diets; meanwhile ω-6 ARA and ω-9 oleic acid levels 425
were reduced in these treatments. Surprisingly, 1:2 diet did not enhance DHA level as 426
expected due to the high DHA dose uptake. As a consequence of the lipid modulation 427
associated to diets, animals fed 1:1 and 2:1 diets exhibited significantly lower plasma428
and erythrocyte ω-6/ω-3 ratios. The ratio between ω-6 and ω-3 FA in blood and tissues 429
is one of the most selective markers of cellular inflammation. Indeed, elevated ratios430
have been associated with an increasing prevalence of chronic inflammatory diseases431
and MetS (Sears 2005).432
433
According to the previous discussed results (Molinar-Toribio et al. 2015), diets 1:1 and 434
2:1 were the most effective to reduce levels of the main CVD risk factors like: TFA, TG, 435
TC, LDL, HbA1c, and significantly enhanced the HDL:LDL ratio. Levels of the 436
inflammatory marker CRP were found decreased by these treatments too. The statistical437
analysis showed a strong correlation between the increase of CRP values and the 438
production of pro-inflammatory eicosanoids from ARA and ω-3 hydroperoxides. 439
Benefits suggested for 1:1 and 2:1 diets reducing levels of CVD risk factors and the 440
inflammatory CRP index, were clearly correlated with a reduction of inflammatory 441
eicosanoids and docosanoids and a global improvement in the lipid profiles discussed 442
above.443
444
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As a conclusion, dietary interventions with marine ω-3 PUFAs seems to be more 445
effective in ameliorating the progression of MetS when compared with vegetable ω-6 446
LA and ω-3 ALA provided by linseed and soybean oils. It is important to highlight that 447
the proportion between marine ω-3 EPA and DHA is crucial to obtain the best448
outcomes. Animals developing MetS from a spontaneous mutation show better results 449
with ratios 1:1 and 2:1 EPA/DHA, and that may be explained by the lower susceptibility 450
to oxidation of EPA vs DHA that leads to lower levels of inflammatory metabolites and 451
oxidative stress, and subsequently, an improvement of MetS indexes. Generally, diets 452
1:1 and 2:1 showed an improvement on CVD and inflammation clinical parameters, 453
strong pro-inflammatory eicosanoids, an activation or preservation of the antioxidant 454
endogenous defenses, and a shift towards greater anti-inflammatory profiles associated 455
to FA composition in plasma and membranes. These results show the need of drawing a 456
new insight into the correct design of fish oil supplements, with proper proportions of 457
EPA and DHA.458
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Table legends: 595
Tab. 1: Plasma and erythrocyte membranes (EM) composition of FA from SHROB rats 596
supplemented with soybean, linseed and fish oil mixtures (EPA/DHA 1:1, 2:1 and 1:2). 597
FAs were extracted using a Bligh and Dyer procedure and then analysed by GC-FID. 598
Results are expressed as percentage of total fatty acids (mg/100mg of TFA). Values are 599
shown as means ± SD. Levels of FA in plasma and membranes were statistically 600
compared between dietary groups. Significant differences for every FA at p<0.05 are 601
shown by different superscript letters. 16:0 (palmitic acid), 16:1 ω7 (palmitoleic acid, 602
PA), 18:0 (stearic acid), 18:1 ω9 (oleic acid, OA), 18:1 ω7 (vaccenic acid), 18:2 ω6 603
(LA), 18:3 ω3 (ALA), 20:3 ω6 (DGLA), 20:4 ω6 (ARA), 20:5 ω3 (EPA), 22:5 ω3 604
(DPA), 22:6 ω3 (DHA)605
606
Tab. 2: Fatty acid desaturases activity indexes from SHROB rats supplemented with 607
fish oil mixtures (EPA/DHA 1:1, 2:1 and 1:2), linseed and soybean oils. FAD indexes 608
were calculated as product/precursor ratio from the TFA data. Values are shown as 609
means ± SD. FAD levels were statistically compared between dietary groups. 610
24
Significant differences for every index at p<0.05 are shown by different superscript 611
letters.612
613
Tab. 3: Levels of lipid mediators in plasma derived from ARA, EPA and DHA 614
obtained from the dietary interventions with SHROB rats. Eicosanoids and docosanoids 615
were isolated and concentrated from biological samples by SPE and then analysed by 616
LC-MS/MS. Results are expressed as ng/mL for derived eicosanoids and docosanoids, 617
and µg/mL for PUFAs. Values are shown as means ± SD. Concentration of lipid 618
derivates were statistically compared between dietary groups. Significant differences for 619
every metabolite at p<0.05 are shown by different superscript letters. 620
621
Tab. 4: Correlation Pearson indexes between lipid mediator levels in plasma and 622
dietary dose of 20C FA (EPA) and 22C FA (DHA), and CRP, SOD, GPX, and CAT 623
levels in SHROB rats supplemented with fish oil mixtures (EPA/DHA 1:1, 2:1 and 1:2), 624
linseed and soybean oils. Positive correlations mean an increase of lipid mediator levels 625
when the dose of EPA and DHA is higher, or levels of CRP, SOD, GPX, and CAT 626
increase. Negative indexes show a decrease of lipid mediators when the rest of 627
parameters increase. P-values lower than 0.05
*
 and 0.01
**
 show that the Pearson index 628
is significantly different to zero at 95% and 99% of confidence, respectively. 629
630
631
Supplementary electronic material legends: 632
S1: Fatty acid composition of soybean, linseed and fish oil mixtures (EPA/DHA 1:1, 633
2:1 and 1:2) supplemented to SHROB rats. FA were methylated and analysed by GC-634
FID. Results are expressed as percentage of total fatty acids (mg/100mg of Total FA). 635
25
Weekly dose of EPA, DHA, ALA, ARA and LA expressed as mg/kg rat. Values are 636
shown as means ± SD. 637
638
S2: Retention times, collision energies and MS/MS transitions for ESI-LC-LIT/MS/MS 639
640
S3: Biochemical parameters related with MetS from supplemented SHROB groups with 641
EPA/DHA 1:1, 2:1 and 1:2; linseed and soybean oil. Data from previous work 642
(Molinar-Toribio et al. 2015). 643
644
1Tab. 1. 
RATIO 1:1 RATIO 2:1 RATIO 1:2
Soybean Linseed
(EPA/DHA) (EPA/DHA) (EPA/DHA) 
FFA FA FFA FA FFA FA FFA FA FFA FA
(Plasma) (EM) (Plasma) (EM) (Plasma) (EM) (Plasma) (EM) (Plasma) (EM)
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD
16:0 
(palmitic)
31.79
a
1.1 23.45
a
0.7 31.66
a
0.8 23.99
a
1.1 31.43
a
0.8 23.50
a
0.7 31.28
a
1.3 22.78
a
0.4 30.20
a
1.4 22.49
a
0.7
16:1 7 
(PA)
10.94
a
1.6 1.83
ab
0.5 10.49
a
0.8 1.40
a
0.2 10.55
a
1.2 1.52
a
0.2 9.12
a
2.2 1.28
a
0.4 10.54
a
2.4 2.24
b
0.2
18:0 
(stearic)
8.60
a
0.9 14.32
a
1.3 7.93
a
0.4 15.34
a
0.4 8.27
a
0.9 15.14
a
0.6 7.90
a
0.9 16.10
a
0.9 8.14
a
1.7 14.06
a
1.3
18:1 9 
(OA)
21.92
a
1 10.82
ab
2.4 22.42
a
0.9 9.00
a
0.6 24.42
ab
1.3 9.78
a
0.9 26.04
b
2.3 9.56
a
1 25.09
b
1 13.05
b
2.2
18:1 7 
(vaccenic)
2.31
a
1.3 1.98
a
0.1 2.28
a
0.1 1.97
a
0.1 2.65
a
0.1 2.07
a
0.1 2.64
a
0.2 1.99
a
0.1 2.58
a
0.1 2.15
b
0.1
18:2 6 
(LA)
9.54
a
0.8 8.21
a
0.3 10.26
ab
0.9 7.67
ab
0.2 10.56
ab
0.9 7.52
bc
0.3 11.29
b
0.5 6.74
c
0.8 10.68
ab
1.4 8.24
ab
0.5
18:33 
(ALA)
0.99
a
0.1 n.d. n.d. 1.05
a
0.1 n.d. n.d. 0.94
a
0.1 n.d. n.d. 0.90
a
0.2 n.d. n.d. 1.97
b
0.4 0.37 0.1
20:3 6 
(DGLA)
n.d. n.d. 1.20
a
0.1 n.d. n.d. 1.27
a
0.2 n.d. n.d. 1.35
a
0.2 n.d. n.d. 1.20
a
0.2 n.d. n.d. 1.27
a
0.3
20:4 6 
(ARA)
3.01
a
0.5 14.22
a
1.1 3.03
a
0.6 15.05
a
0.5 3.25
a
0.5 16.78
b
0.4 4.65
b
1.1 19.65
c
1.1 3.86
ab
0.8 16.55
b
0.6
20:5 3 
(EPA)
1.34
a
0.3 2.20
a
0.4 1.30
a
0.2 2.21
a
0.3 0.66
b
0.1 1.24
b
0.2 0.45
b
0.1 0.77
c
0.2 0.81
b
0.2 1.47
b
0.3
22:5 3 
(DPA)
1.74
a
0.3 3.10
a
0.3 2.36
a
0.1 3.80
b
0.1 1.15
c
0.1 2.70
ac
0.3 0.84
d
0.2 2.41
c
0.4 1.36
ac
0.2 3.13
a
0.5
22:6 3 
(DHA)
5.44
a
0.9 9.11
a
0.7 5.00
a
0.5 8.22
a
0.4 3.95
b
0.3 8.47
a
0.1 2.85
c
0.4 6.70
b
0.6 2.76
c
0.4 6.36
b
0.3
∑ ω3 9.51a 0.4 14.41a 0.4 9.71a 0.2 14.22a 0.3 6.70b 0.2 12.40b 0.2 5.04c 0.2 9.88c 0.4 6.90b 0.3 11.34d 0.3
∑ ω6 12.55a 0.6 23.63a 0.5 13.29ab 0.8 23.99a 0.3 13.81b 0.7 25.65b 0.3 15.94c 0.8 27.59c 0.7 14.54bc 1.1 26.06b 0.4
∑ SFA 40.39a 1.1 37.77ab 1 39.59a 0.6 39.33a 0.8 39.70a 0.9 38.64a 0.6 39.18a 1.2 38.88a 0.6 38.34a 1.5 36.56b 1
∑ MUFA 35.17a 1.3 14.63a 1 35.19a 0.6 12.36b 0.3 37.62a 0.9 13.36ac 0.4 37.80a 1.6 12.83bc 0.5 38.21a 1.5 17.44d 0.8
∑ PUFA 22.06a 0.5 38.04a 0.5 23.00a 0.4 38.21a 0.3 20.51b 0.4 38.06a 0.3 20.98b 0.4 37.47a 0.6 21.44ab 0.6 37.4a 0.4
ω6/ω3 1.32 1.64 1.37 1.69 2.06 2.07 3.16 2.79 2.11 2.30
Table(s)
2Tab. 2 
RATIO 1:1 RATIO 2:1 RATIO 1:2
Soybean Linseed
(EPA/DHA) (EPA/DHA) (EPA/DHA)
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD
SCD16[palmitoleic/palmitic] 0.3
a
0.04 0.2
a
0.02 0.3
a
0.03 0.2
a
0.05 0.2
a
0.04
SCD-18 [oleic/stearic] 2.3
a
0.5 2.2
a
0.3 2.9
b
0.7 3.2
b
0.8 2.7
b
0.7
5D [ARA/DGLA] 8.1a 0.7 9.3a 1.3 8.7a 1.5 12.9b 2.6 10.1c 1.6
6D [DGLA/LA] 0.1a 0.01 0.1a 0 0.1a 0.01 0.1a 0.01 0.1a 0
5/6D [EPA/ALA] 4.3a 0.6 4.6a 0.5 2.4b 0.2 1.4c 0.3 1.4c 0.4
5D [DHA/DPA] 5.3a 0.8 3.7b 0.5 5.3a 0.3 4.9ab 0.6 3.1b 0.3
3Tab. 3 
RATIO 1:1 RATIO 2:1 RATIO 1:2
Soybean Linseed
(EPA/DHA) (EPA/DHA) (EPA/DHA)
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD
Eicosanoids from EPA (ng/mL)
5HEPE n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
12HEPE 401.7
ab
252.3 237.4
a
73.7 625.1
b
304.1 284.7
a
210.1 254.8
a
224
15HEPE n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
12HpEPE 1507.8
a
293.1 1385.3
a
242.9 2512.8
b
106 4393.6
c
1121 1584.4
a
537.8
15HpEPE n.d. n.d. 239
a
130.6 494.6
b
171.7 n.d. n.d. 240.2
a
108.8
8iso-PGF3a n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
TXB3 5.1
a
1.3 4.5
a
0.3 6.8
b
1.7 5
ab
1 4.8
a
2.1
PGD3/E3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Docosanoids from DHA (ng/mL)
17HDoHE 150.7
a
105.5 85.3
a
32.4 306.9
b
102.9 159.5
a
81.3 106.1
a
77.6
11HDoHE n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
4HDoHE n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
17HpDoHE 2580.7
a
431.6 2317
a
203.9 4208.3
b
839 3819.8
b
1216.6 2726
a
786
RvD1 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
PDx n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Eicosanoids from ARA (ng/ml)
11HETE 15.5
a
11 5.1
a
5.3 16.6
a
9.1 30.3
b
18.3 9.6
a
10.4
PGE2 13.7
a
10.2 15.6
a
6.8 81.7
b
55.1 83.4
b
35.4 26
a
14.3
LTB4 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
8isoPGF2a n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
PUFA precursors (ng/uL)
EPA 9.7
a
1.5 6.8
b
0.8 2.9
c
0.7 1.7
d
0.8 2.5
cd
0.7
DHA 51.9
a
5.5 33.5
b
7.2 22.7
c
6.3 17.3
cd
4 15.1
d
3.8
ARA 68.3
a
12.4 48.1
bc
3.8 38.2
c
10.2 50.8
b
10.3 37.5
c
3.6
4Tab. 4 
Intake of EPA Intake of DHA CRP concentration SOD concentration GPX concentration CAT concentration
Pearson index P-value Pearson index P-value Pearson index P-value Pearson index P-value Pearson index P-value Pearson index P-value
12HEPE -0.06 0.49 0.79 0.11 0.07 0.47 0.35 0.33 -0.62 0.19 -0.34 0.33
12HpEPE -0.98 0.009
**
-0.65 0.17 0.99 0.006
**
-0.95 0.02
*
-0.72 0.14 -0.76 0.12
15HpEPE -1.00 0.001
**
1.00 0.001
**
1.00 0.001
**
-1.00 0.001
**
-1.00 0.001
**
-1.00 0.001
**
TXB3 -0.22 0.39 0.66 0.17 0.26 0.37 0.15 0.42 -0.71 0.15 -0.40 0.30
17HDoHE -0.34 0.33 0.57 0.21 0.37 0.32 0.04 0.48 -0.79 0.11 -0.50 0.25
17HpDoHE -0.76 0.12 0.04 0.48 0.81 0.09 -0.50 0.25 -0.92 0.04
*
-0.71 0.15
11HETE -0.98 0.01
*
-0.54 0.22 0.90 0.05 -0.83 0.08 -0.82 0.09 -0.94 0.03
*
PGE2 -0.84 0.08 -0.18 0.41 0.91 0.04
*
-0.68 0.16 -0.86 0.07 -0.69 0.16
EPA 0.78 0.11 0.34 0.33 -0.90 0.04
*
0.76 0.12 0.65 0.17 0.48 0.26
DHA 0.68 0.16 0.38 0.31 -0.84 0.08 0.74 0.13 0.50 0.25 0.32 0.34
S1 
RATIO 1:1
(EPA:DHA) 
RATIO 2:1
(EPA:DHA) 
RATIO 1:2
(EPA:DHA) SOYBEAN LINSEED
FATTY ACID MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD
14:0 4.37 0.05 3.97 0.01 4.73 0.02 0.96 0.02 0.06 0.01
16:0 10.15 0.16 9.09 0.03 10.98 0.13 17.78 0.10 5.73 0.03
16:1 7 (PA) 4.99 0.04 4.57 0.02 5.39 0.03 0.90 0.03 0.11 0.01
18:0 2.94 0.03 2.95 0.00 2.97 0.01 2.07 0.01 4.75 0.02
18:1 9 (OA) 6.41 0.06 6.18 0.00 6.61 0.04 18.75 0.03 21.37 0.06
18:1 7 1.91 0.03 1.93 0.02 1.95 0.02 1.52 0.02 1.11 0.01
18:2 6 (LA) 0.65 0.01 0.61 0.00 0.65 0.02 47.55 0.01 16.76 0.03
20:0 0.32 0.01 0.39 0.01 0.20 0.00 0.00 0.00 0.00 0.00
18:3 3 (ALA) 0.36 0.01 0.32 0.00 0.33 0.02 4.00 0.04 50.02 0.10
20:1 9 0.98 0.03 1.39 0.01 0.63 0.02 1.43 0.09 n.d. n.d.
18:4 3 1.51 0.02 1.56 0.02 1.64 0.00 0.15 0.00 n.d. n.d.
20:2 6 0.21 0.00 0.28 0.01 0.17 0.01 0.20 0.05 n.d. n.d.
20:3 6 0.22 0.01 0.27 0.01 0.15 0.00 0.00 0.00 n.d. n.d.
20:4 6 (ARA) 1.68 0.04 1.98 0.03 1.16 0.02 0.40 0.02 n.d. n.d.
22:1 11 1.14 0.01 1.58 0.02 0.45 0.01 1.08 0.00 n.d. n.d.
22:1 9 0.28 0.03 0.37 0.03 0.19 0.02 0.25 0.02 n.d. n.d.
20:4 3 1.02 0.02 1.31 0.02 0.75 0.01 0.20 0.03 n.d. n.d.
20:5 3 (EPA) 25.09 0.10 32.43 0.06 17.33 0.03 0.70 0.02 n.d. n.d.
24:1 9 0.38 0.00 0.55 0.02 0.25 0.01 0.28 0.05 n.d. n.d.
22:5 3 (DPA) 4.30 0.05 5.24 0.02 2.60 0.12 0.26 0.01 n.d. n.d.
22:6 3 (DHA) 25.70 0.21 17.98 0.03 34.85 0.10 1.15 0.03 n.d. n.d.
Total 3 PUFA 57.97 0.07 58.84 0.03 57.51 0.05 6.47 0.02 50.02 0.10
Total 6 PUFA 2.76 0.01 3.14 0.01 2.14 0.01 48.15 0.02 16.76 0.03
Total SFA 18.52 0.22 17.05 0.02 19.68 0.12 21.17 0.10 10.63 0.06
Total MUFA 17.22 0.12 17.14 0.07 17.43 0.11 24.21 0.11 22.59 0.06
Total PUFA 64.26 0.33 65.81 0.08 62.90 0.24 54.62 0.03 66.78 0.11
weekly dose of EPA 159.30 mg/kg rat 205.84 mg/kg rat 110.03 mg/kg rat 4.45 mg/kg rat
weekly dose of DHA 163.12 mg/kg rat 114.15 mg/kg rat 221.24 mg/kg rat 7.31 mg/kg rat
weekly dose of ARA 10.65 mg/kg rat 12.55 mg/kg rat 7.37 mg/kg rat 2.54 mg/kg rat
weekly dose of ALA 2.29 mg/kg rat 2.06 mg/kg rat 2.09 mg/kg rat 25.39 mg/kg rat 317.56 mg/kg rat
weekly dose of LA 4.13 mg/kg rat 3.88 mg/kg rat 4.15 mg/kg rat 301.86 mg/kg rat 106.39 mg/kg rat
S2 
Compound Retention Time
(min)
LIT parameters
Collision energy (eV) Quantification transition (m/z)
8iso-PGF3α 6.79 30 351>253
TXB3 6.97 19 367>195
PGD3/PGE3 7.67 19 349>313
8iso-PGF2α 8.28 28 353>299
PGE2 9.09 20 351>315
RvD1 9.80 25 375>141
PDx 12.89 30 359>153
LTB4 13.79 27 335>195
15HpEPE 17.36 20 333>315
12HpEPE 17.80 25 333>315
15HEPE 17.92 27 317>219
12HEPE 18.72 27 317>179
5HEPE 20.47 25 317>255
17HpDoHE 21.90 26 359>341
17HDoHE 21.94 27 343>245
11HETE 22.09 30 319>167
12HETEd8 22.66 30 325>307
11HDoHE 23.20 27 343>149
4HDoHE 23.64 27 343>281
EPA 24.43 27 301>257
DHA 24.93 30 327>283
ARA 25.10 30 303>259

